LipiGesic® M Fills the Need for Fast, Effective Migraine Treatment Described in the Wall Street Journal

SCHOFIELD Wis., Aug. 16, 2012 /PRNewswire/ -- "People need migraine drugs that have a rapid onset of action, that take the pain away and keep it away," said Dr. Richard Lipton, director of the Montefiore Headache Center in New York as quoted in the August 7, 2012 edition Wall Street Journal article entitled "Fresh Target in Hunt for a Migraine Cure."

LipiGesic® M fills those needs. The results of a double-blind, placebo controlled study conducted by Roger K. Cady, MD, Jerome Goldstein, MD, Robert Nett, MD, et al show that LipiGesic M provides a safe, highly-effective treatment of acute migraine when taken at the first sign of headache and when used as directed. These clinical trial results were published in the July 2011 issue of Headache: The Journal of Head and Face Pain, a top-tier medical publication.

LipiGesic M, is a homeopathic, sublingual, over-the-counter (OTC) migraine medication with an excellent safety profile and a high efficacy rate in the treatment of migraine pain and associated symptoms.

"When clinical outcomes are compared, LipiGesic M works as well as, if not better than the number-one selling prescription migraine medication," said Russ Mitchell, CEO of PuraMed BioScience®, Inc., developers, of LipiGesic M. "Based on our current research, LipiGesic M's primary impact is inhibiting nitric-oxide synthase along with inhibition of NF Kappa Beta and TNF alpha."

Nitric oxide synthase, NF Kappa Beta, and TNF alpha are all inflammatory markers known to play a role in the inflammation that occurs during a migraine attack.

"Though we have not yet tested LipiGesic M's effect on the calcitonin gene-related peptide (CGRP) marker that was highlighted in the August 7, Wall Street Journal article," said Mitchell, "we do know that LipiGesic M is very effective in blocking the three other markers known to play a role in the development migraine."

There are no known drug interactions with LipiGesic M, so people who are taking medications for other health problems can use LipiGesic M to treat their migraines. LipiGesic M also has no contraindication for heart disease or stroke. Prior to taking any medication, people should talk to their healthcare provider.

"Many chemicals used to create prescription drugs have the potential to damage the body," said Mitchell. "Combining feverfew and ginger, which have been around for hundreds of years, into a homeopathic, sublingual gel allows patients to treat their migraines effectively without debilitating side effects, fear of causing liver damage, or feelings of a migraine hangover, which is experienced by some sufferers taking other medications. The formulation and delivery method allow the full-strength ingredients to reach the bloodstream quickly. Patients no longer need to trade the pain of migraine for the risk of side effects.

"LipiGesic M also works fast," said Mitchell. "When taken at the first sign of migraine, users often report they feel the aura or pain begin to leave within the first 10 minutes. Even if the headache recurs the next day and another treatment is needed, users do not have to fear rebound headache; LipiGesic M does not include aspirin or acetaminophen."

LipiGesic M is available over-the-counter at Walgreens and CVS/pharmacy stores nationwide. Consumers can also download a $5 manufacturers coupon or order the product online at

To learn more about this homeopathic migraine product and read the clinical study, visit

About the Company:
PuraMed BioScience, Inc., engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic® M, which provides acute relief from migraine headaches; the company also has plans to launch LipiGesic® PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic® H for common tension headaches. 

For more information on PuraMed BioScience, visit, join the company's group page on Facebook by searching "PuraMed BioScience" and/or follow the company on Twitter at

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Russell Mitchell, Chairman and CEO
PuraMed BioScience, Inc.
[email protected] 
Product Website: 
Corporate Website:

SOURCE PuraMed BioScience, Inc.